SEATTLE, WA / ACCESSWIRE / April 10, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
Aptevo Reports 2023 Financial Results and Provides a Business Update
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split
Aptevo Reports 3Q23 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 10, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436.